At Asymchem we are proud of the strides that we have made since our founding in 1999, providing R&D and one-stop production services to the world’s top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future. By improving the capabilities our partners need now, and maintaining the agility needed to support innovation, we’ve built a knowledge and experience base that we’re ready to share.
Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem.
Our 8 R&D and manufacturing sites are located in P.R. China and are regularly inspected by regulatory bodies such as the USFDA. Our expertise lies in developing and applying innovative technologies such as green chemistry for scaleup of technically complex API's, with the added advantage of in-house raw materials' manufacturing to control availability and lead-times. From initial development of a synthetic chemical process through to manufacturing, Asymchem’s proven team of experienced process and engineering teams has the knowledge to help our clients get things done.
Asymchem's toolbox of capabilities include continuous flow reactions technologies, biocatalysis, asymmetric synthesis, HPAPI, cryogenic, catalytic hydrogenation, and others.
Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem.
Our 8 R&D and manufacturing sites are located in P.R. China and are regularly inspected by regulatory bodies such as the USFDA. Our expertise lies in developing and applying innovative technologies such as green chemistry for scaleup of technically complex API's, with the added advantage of in-house raw materials' manufacturing to control availability and lead-times. From initial development of a synthetic chemical process through to manufacturing, Asymchem’s proven team of experienced process and engineering teams has the knowledge to help our clients get things done.
Asymchem's toolbox of capabilities include continuous flow reactions technologies, biocatalysis, asymmetric synthesis, HPAPI, cryogenic, catalytic hydrogenation, and others.
Location: China, Tianjin, Binhai New Area
Employees: 5001-10000
Founded date: 1999
Investors 1
| Date | Name | Website |
| - | Infinity G... | infinity-e... |
Mentions in press and media 6
| Date | Title | Description |
| 02.02.2026 | From PopMart to JD.com: Britain and China rush to forge business deals as diplomatic thaw takes hold | U.K’s prime minister met with the Chinese president and secured deals that would see hundreds of millions worth of new investments from Chinese businesses. Beijing promised to expand market access for British companies and improve a busines... |
| 05.08.2025 | Asymchem Advances Flow Chemistry Capabilities at UK Sandwich Site with In-House Equipment Installation | Leading CDMO Company for Pharmaceutical Solutions Asymchem has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility. SANDWICH, UNITED KINGDOM, August 5, 2025 /EINPresswire.com/ -- Asymchem, a glo... |
| 07.04.2022 | AI companies join forces to boost data use in manufacturing; Construction complete at 2 sites for added API capacity | Two AI companies have teamed up to help speed up the delivery of drugs with higher output and improved quality. TetraScience, a Boston-based R&D data cloud company, joined forces with AI SaaS provider Aizon Wednesday. The ... |
| 30.11.2021 | Asymchem Laboratories Plans to Raise $968 Million in Hong Kong IPO | By P.R. Venkat Shenzhen-listed Asymchem Laboratories Tian Jin Co. is planning to raise as much as 7.55 billion Hong Kong dollars ($968 million) via a share offering in Hong Kong, joining a list of Chinese companies looking to complete deals... |
| 25.03.2021 | Asymchem Expands Manufacturing Capacity for Oligonucleotides | |
| 13.10.2020 | China’s Asymchem Lab Hits New High on Raising USD341.5 Mln in Private Placement | (Yicai Global) Oct. 13 -- Asymchem Laboratories’ share price hit an all-time high today after the Chinese contract drug researcher and developer succeeded in raising CNY2.3 billion (USD341.5 million) in a private placement scheme despite up... |